| Print
UCB (UCB)
UCBThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).
Address
60, Allee de la Recherche
Brussels
BEL
1070
Telephone
+ 32 2 5599414
Forecast key dates
| Name | Key Date |
|---|---|
| UCB SA Fourth Quarter Earnings Conference Call for 2025 | 2026-02-27T14:00:00 |
| UCB SA Fourth Quarter Earnings Results for 2025 | 2026-02-27T07:00:00 |
| UCB SA Annual Report for 2025 | 2026-02-27T00:00:00 |
| UCB SA Second Quarter Earnings Conference Call for 2025 | 2025-07-25T08:00:00 |
| UCB SA Second Quarter Earnings Results for 2025 | 2025-07-25T00:00:00 |
| UCB SA Annual General Meeting for 2025 | 2025-05-02T11:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| UCB SA Annual General Meeting for 2025 | 2025-05-02T11:00:00 |
| UCB SA Annual Report for 2024 | 2025-02-28T00:00:00 |
| UCB SA Fourth Quarter Earnings Conference Call for 2024 | 2025-02-27T14:00:00 |
| UCB SA Fourth Quarter Earnings Results for 2024 | 2025-02-27T07:00:00 |
| UCB SA Second Quarter Earnings Conference Call for 2024 | 2024-07-25T08:00:00 |
| UCB SA Second Quarter Earnings Result for 2024 | 2024-07-25T00:00:00 |
| JP Morgan European Healthcare Forum | 2024-06-20T00:00:00 |
| Citi’s European Healthcare Conference | 2024-06-19T00:00:00 |
| June 2024 UCB Capital Market Briefing | 2024-06-12T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2025 AJ Bell. All rights reserved.